QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

Core Insights - QIAGEN N.V. reported fourth-quarter 2024 adjusted earnings per share (EPS) of 61 cents, an 11% increase from the previous year, but 1.6% below the Zacks Consensus Estimate [1][3] - The company’s net sales for the fourth quarter reached $521.2 million, a 4$1.98 billion, reflecting a 1% increase from the previous year [3] Financial Performance - Adjusted operating income rose 11.6% year over year to $156.5 million, with an adjusted operating margin expanding by 248 basis points to 30$346.8 million, with the adjusted gross margin improving by 131 basis points to 66.5% [7][8] - The company ended the fourth quarter with cash and short-term investments of $1.2 billion, up from$1.1 billion at the end of 2023, while long-term debt increased to $1.34 billion [10] Revenue Breakdown - Sample technologies revenues decreased by 2$162 million, while diagnostic solutions revenues increased by 9% to $196 million [4] - QuantiFERON revenues grew by 14$82 million, and genomics/NGS revenues were $66 million, up 1$2.28 [11] - The company anticipates first-quarter net sales to rise by approximately 3% at CER, with adjusted EPS expected to be at least 50 cents [12] - QIAGEN's performance reflects a resilient portfolio with a focus on profitable growth despite challenging market conditions [13][14]